Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 2, 2011, Pages 301-313

  Hadji, Peyman ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Bisphosphonate; Bone metastasis; Bone turnover marker; Denosumab; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; ANTIRESORPTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; DENOSUMAB; GOSERELIN; IBANDRONIC ACID; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EAR INFECTION; ENDOCARDITIS; ENZYME INHIBITION; FEMUR FRACTURE; HEART ARREST; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INFECTION; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PATIENT CARE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN INFECTION; SOLID TUMOR; TREATMENT DURATION; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS;

EID: 80053961209     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.03.007     Document Type: Review

References (122)

1. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
2. Weinfurt K.P., Castel L.D., Li Y., Timbie J.W., Glendenning G.A., Schulman K.A. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42:164-175.
3. Saad F., Lipton A., Cook R., Chen Y.-M., Smith M., Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
4. Major P.P. Preserving functional independence in elderly patients with cancer-associated bone disease: the role of zoledronic acid. Aging Health 2009, 5:151-164.
5. Xgeva (denosumab) injection [package insert]. Thousand Oaks, CA: Amgen Inc.; 2010.
6. Bock O., Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 2008, 3:279-297.
7. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010, 73:156-166.
8. Ziller V., Kalder M., Albert U.S., et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009, 20:431-436.
9. Mangiapane S., Hoer A., Gothe H., Barghout V., Haeussler B. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol 2006, 24:698s. [Abstract 18623].
10. Hatoum H.T., Lin S.J., Smith M.R., Barghout V., Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008, 113:1438-1445.
11. Pouilles J.M., Tremollieres F., Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res 1995, 10:1531-1536.
12. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009, 69:73-82.
13. Shapiro C.L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306-3311.
14. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223.
15. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
16. Saad F., Adachi J.D., Brown J.P., et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008, 26:5465-5476.
17. Smith M.R., Fallon M.A., Goode M.J. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003, 61:127-131.
18. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
19. Chang S.S. Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer. Urology 2003, 62:29-35.
20. Pfeilschifter J., Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570-1593.
21. Terpos E., Sezer O., Croucher P.I., et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009, 20:1303-1317.
22. Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009, 301:513-521.
23. Pavlakis N., Schmidt R., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005, CD003474.
24. Ibrahim A., Scher N., Williams G., et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003, 9:2394-2399.
25. Ishizaka K., Machida T., Kobayashi S., Kanbe N., Kitahara S., Yoshida K. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007, 14:1071-1075.
26. Israeli R.S., Rosenberg S.J., Saltzstein D.R., et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007, 5:271-277.
27. Magno C., Anastasi G., Morabito N., et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 2005, 47:575-580. [discussion follows].
28. Planas J., Trilla E., Raventos C., et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 2009, 104:1637-1640.
29. Ryan C.W., Huo D., Bylow K., et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007, 100:70-75.
30. Ryan C.W., Huo D., Demers L.M., Beer T.M., Lacerna L.V. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006, 176:972-978. [discussion follows].
31. Saad F., Abrahamsson P.A., Miller K. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int 2009, 104:1573-1579.
32. Satoh T., Kimura M., Matsumoto K., et al. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 2009, 115:3468-3474.
33. Brufsky A., Bundred N., Coleman R., et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13:503-514.
34. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112:1001-1010.
35. Eidtmann H., de Boer R., Bundred N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010, 21:2188-2194.
36. Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26:4739-4745.
37. Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at: American Society of Clinical Oncology 2009 Breast Cancer symposium; October 8-10, 2009, San Francisco, CA [Abstract 213].
38. Shapiro C.L., Halabi S., Hars V., et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results for CALGB trial 79809. Eur J Cancer 2011, 47:683-689.
39. Swenson K.K., Nissen M.J., Anderson E., Shapiro A., Schousboe J., Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 2009, 7:101-107.
40. Confavreux C.B., Fontana A., Guastalla J.P., Munoz F., Brun J., Delmas P.D. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41:346-352.
41. Greenspan S.L., Brufsky A., Lembersky B.C., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008, 26:2644-2652.
42. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
43. Delmas P.D., Balena R., Confravreux E., Hardouin C., Hardy P., Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997, 15:955-962.
44. Van Poznak C., Hannon R.A., Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975.
45. Saarto T., Vehmanen L., Blomqvist C., Elomaa I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 2008, 26:4289-4295.
46. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113:364-371.
47. Ottewell P.D., Deux B., Monkkonen H., et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008, 14:4658-4666.
48. Ottewell P.D., Monkkonen H., Jones M., Lefley D.V., Coleman R.E., Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100:1167-1178.
49. Winter M.C., Holen I., Coleman R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475.
50. Ottewell P.D., Lefley D.V., Cross S.S., Evans C.A., Coleman R.E., Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010, 126:522-532.
51. Neville-Webbe H.L., Coleman R.E., Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010, 102:1010-1017.
52. Dearnaley D.P., Mason M.D., Parmar M.K., Sanders K., Sydes M.R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.
53. Dearnaley D.P., Sydes M.R., Mason M.D., et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003, 95:1300-1311.
54. Diel I.J., Jaschke A., Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
55. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
56. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
57. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
58. Coleman R.E., Winter M.C., Cameron D., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
59. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
60. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at: 33rd annual San Antonio Breast Cancer symposium; December 8-12, 2010, San Antonio, TX [Abstract S4-5].
61. Mitchell D.Y., Barr W.H., Eusebio R.A., et al. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 2001, 18:166-170.
62. Porras A.G., Holland S.D., Gertz B.J. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999, 36:315-328.
63. Kimmel D.B. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007, 86:1022-1033.
64. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9:3-13.
65. Fizazi K., Bosserman L., Gao G., Skacel T., Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009, 182:509-515. [discussion follows].
66. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564-1571.
67. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.
68. Smith M.R., Egerdie B., Hernandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
69. Prolia [summary of product characteristics]. Breda, The Netherlands: Amgen Europe B.V.; 2010.
70. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:785-786.
71. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
72. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
73. Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221-1228.
74. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
75. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011, (February). [Epub ahead of print].
76. Lipton A., Cook R.J., Coleman R.E., et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007, 7:346-353.
77. Coleman R.E., Purohit O.P., Black C., et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999, 10:311-316.
78. Jagdev S.P., Purohit P., Heatley S., Herling C., Coleman R.E. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001, 12:1433-1438.
79. Mortensen L., Charles P., Bekker P.J., Digennaro J., Johnston C.C. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998, 83:396-402.
80. McCloskey E., Paterson A., Kanis J., Tahtela R., Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 2010, 46:558-565.
81. Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease. Presented at: International bone and mineral society Davos workshops: bone biology and therapeutics; March 9-14, 2008, Davos, Switzerland [Abstract 199].
82. Skerjanec A., Berenson J., Hsu C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003, 43:154-162.
83. Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
84. Grey A., Bolland M.J., Wattie D., Horne A., Gamble G., Reid I.R. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009, 94:538-544.
85. Burckhardt P. Ibandronate in oncology. Cancer 1997, 80:1696-1698.
86. Thiebaud D., Burckhardt P., Kriegbaum H., et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997, 103:298-307.
87. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
88. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997, 75:602-605.
89. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005, 20:1315-1322.
90. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
91. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
92. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
93. Lipton A., Steger G.G., Figueroa J., et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008, 14:6690-6696.
94. Body J.J., Lipton A., Gralow J., et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010, 25:440-446.
95. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
96. Eisman J.A., Bone H.G., Hosking D.J., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26:242-251.
97. Brown JP, Dempster DW, Ding B, et al. Remodeling status in postmenopausal women who discontinued denosumab treatment. Presented at: ASBMR 2010 annual meeting; October 15-19, 2010, Toronto, ON, Canada [Abstract 1069].
98. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62.
99. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 47:169-180.
100. Bauer D.C. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?. J Bone Miner Res 2011, 26:239-241.
101. Gnant M., Mlineritsch B., Stoeger H., et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010, 28:7S. [Abstract 533].
102. Gnant M.F., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
103. Van Poznak C.H., Temin S., Yee G.C., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011, 29:1221-1227.
104. Tchekmedyian NS, Chen Y-M, Saad F. Bone disease progression (BDP) and overall disease progression (ODP) correlate with significantly decreased time to onset of skeletal-related events (SREs) and increased risks of SREs. Presented at: 33rd ESMO congress; September 12-16, 2008, Stockholm, Sweden [Abstract 822PD].
105. Dincer M., Altundag K., Harputluoglu H., Aksoy S., Cengiz M., Gullu I. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol 2008, 25:356-359.
106. Duck L, Delforge M, Doyen C, et al. Long term treatment with zoledronic acid (≥2 years) in patients with metastatic bone disease or multiple myeloma: 6-month results from the LOTUZ study. Presented at: 45th annual meeting of the American Society of Clinical Oncology; May 29-June 2, 2009, Orlando, FL [Abstract 9630].
107. Onishi T, Singh V, Rosenzweig M, Sereika SM, Brufsky AM. Long term treatment with intravenous bisphosphonates in metastatic breast cancer (mBC). Poster presented at the 45th annual meeting of the American Society of Clinical Oncology; May 29-June 2, 2009, Orlando, FL [Abstract 1035].
108. Stopeck A, Martin M, Ritchie D, et al. Effect of denosumab versus zoledronic acid treatment In patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Presented at: 33rd annual San Antonio Breast Cancer symposium; December 8-12, 2010, San Antonio, TX [Abstract P6-14-01].
109. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
110. Raje N, Vescio R, Montgomery CW, et al. Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: interim-analysis results of the Z-MARK study. Presented at: 52nd ASH annual meeting and exposition; December 4-7, 2010, Orlando, FL [Abstract 2971].
111. Tanvetyanon T., Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006, 17:897-907.
112. Coleman R, Bundred N, de Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd annual San Antonio Breast Cancer symposium; December 9-13, 2009, San Antonio, TX [Abstract 4082].
113. Zometa® (zoledronic acid) [summary of product characteristics]. West Sussex, UK: Novartis Europharm Limited; 2003.
114. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
115. Lipton A, Siena S, Rader M, et al. Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Presented at: 35th ESMO congress; October 8-12, 2010, Milan, Italy [Abstract 1249].
116. Anastasilakis A.D., Toulis K.A., Goulis D.G., et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009, 41:721-729.
117. United States Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs. Denosumab. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM176595.pdf. Published August 13, 2009 [accessed 4.05.10].
118. Reid I.R., Gamble G.D., Mesenbrink P., Lakatos P., Black D.M. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010, 95:4380-4387.
119. Leibbrandt A., Penninger J.M. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008, 1143:123-150.
120. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204:321-329.
121. Fizazi K, Carducci M, Smith M, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with castration-resistant prostate cancer. Presented at: 46th annual meeting of the American Society of Clinical Oncology; June 4-8, 2010, Chicago, IL [Abstract LBA4507].
122. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at: joint ECCO 15-34th ESMO multidisciplinary congress; September 20-24, 2009, Berlin, Germany [Abstract 20LBA].